In 2013, the Dolphins made defensive end Dion Jordan the highest selected University of Oregon product since Joey Harrington in 2002. Like Harrington, the selection of Jordan did not prove to be a good one. 
Jordan, the No. 3 overall pick in the draft, was only a part-time player as a rookie and his sophomore campaign did not get off to a promising start. On this date in 2014, Jordan was banned for the first four games of the season after a violation of the league’s policy on performance-enhancing drugs.
For his part, Jordan claimed that he tested “positive for stimulants that are banned under the NFL policy.” In September, his suspension was lifted as a part of the league’s overhaul of its drug policy, but he was immediately hit with another four-game suspension for a separate infraction. Jordan wound up missing the first six games of the 2014 season and underwhelmed in the ten games he did play.
In 2015, Jordan lost his entire season after the NFL found that he diluted one of his test samples. He was conditionally reinstated in 2016, but the Dolphins were forced to place him on the NFI list as he was recovering from a knee surgery that he did not inform the team about. After a second knee surgery in the fall, the Dolphins were fed up, and they opted against activating Jordan for the home stretch of the season.
The good news here is that Jordan may finally be on the right track. Last year, he hooked on with the Seahawks and showed promise in a small five-game sample as he tallied four sacks. This offseason, the Seahawks retained Jordan on a one-year, $1.9MM deal. He underwent a minor knee procedure in June, but Seattle expects to have him back in time for the preseason.